Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus Article 3 Undervalued Names Too Cheap to IgnoreBy Nathan Reiff. Article Posted: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with valuation metrics that are historically low and/or competitive relative to peers or the broader market. They also provide added benefits such as compelling dividends or promising product developments. While value opportunities can be harder to find when many growth names are again attracting investor attention—and while some apparent bargains hide deteriorating operations—well-established, stable names can still be attractive value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Oil is soaring, but today America's trading partners are exchanging their dollars for gold, not the other way around—don't believe me? Then you need to explain why gold is now America's largest export. I'm Garrett Goggin, America's leading gold analyst with 25 years experience finding gold stocks before they take off, and today I'm outlining the next 5X company you need to own now. I found a company that just produced its first gold, and on May 20th, this company will post its first revenues—until a company posts its first revenue, Wall Street and Main Street ignore mining stocks, which is why today my favorite gold stock is a small miner that just produced its first gold. Click here for the free gold stock report before May revenues hit Although shares have climbed more than 28% in the past year, pushing market capitalization toward $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45—well below the medical-industry average near 27. Analysts expect continued growth: earnings are projected to rise nearly 10% next year, and the stock shows a roughly 5% upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received European Commission approval for subcutaneous injection in late 2025 and generated about $8.4 billion in sales in Q4 2025, up nearly 7% year-over-year. Keytruda also shows potential in ovarian cancer, which could broaden its patient base as Merck prepares for patent expiry in 2028. Merck's broader drug pipeline is expanding as well. The company recently announced phase 3 results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, Merck is reorganizing its human health division into two units to make it easier to grow non-cancer drug sales ahead of Keytruda's loss of exclusivity. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) has seen shares fall roughly 37% over the last year as tariffs and inflation pressure the food-and-beverage company. In Q1 fiscal 2026 (ended Nov. 2, 2025), Campbell's reported modest year-over-year declines in organic net sales and consumption, with adjusted EPS down about 13%. Margin improvement has been limited so far despite cost-saving initiatives. The near term will likely remain challenging given weak fiscal-year guidance, but the company's improving supply chain and strong brand loyalty—especially for premium offerings—should provide some protection. Changes in tariffs could also ease some pressure. Campbell's remains an attractive dividend play, offering a yield of 5.9%, though its payout ratio is relatively high at more than 80%. Its P/E of 13.5 is the lowest in about four years, which may convince some investors the stock is worth the risk despite Wall Street caution. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice distributor US Foods (NYSE: USFD) has moved in the opposite direction of Campbell's—shares rose roughly 33% over the past year—yet its valuation is still reasonable relative to growth prospects, with a P/E of 31.6. Fundamentally, US Foods is making progress: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year-over-year. Better inventory management and cost-of-goods savings are helping margins, and a $4 billion capital deployment plan should support continued revenue and adjusted EBITDA momentum. Analysts rate USFD a Moderate Buy based on 11 Buys and 2 Holds, and see roughly 15% upside potential. These companies illustrate how value opportunities can still be found among well-known, established firms—though investors should weigh each company's sector-specific risks, near-term headwinds, and longer-term catalysts before committing capital. | 
